Therapeutic Potential of HDL in Cardioprotection and Tissue Repair

Linthout, Sophie Van; Frias, Miguel; Singh, Neha; Geest, Bart De

doi:10.1007/978-3-319-09665-0_17

Cited by 43 publications

(46 citation statements)

References 208 publications

(231 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results from this study indicate that Lipo‐NPs, consisting of a combination of EVs and lipoproteins, have similar anti‐inflammatory and protective functions as patient‐matched ADSC‐EVs. These therapeutic properties may stem from both EVs and lipoproteins, as the latter have also previously been shown to display anti‐apoptotic and anti‐inflammatory potential in cardiovascular,76 liver,77 and neurodegenerative diseases 78. Additionally, Lipo‐NPs potentially have dual use as endogenous anti‐inflammatory agents and exogenous (drug) delivery vehicles.…”

Section: Resultsmentioning

confidence: 99%

Adipose‐Derived Biogenic Nanoparticles for Suppression of Inflammation

Tian

Ticer

Wang

et al. 2020

Small

View full text Add to dashboard Cite

Extracellular vesicles secreted from adipose‐derived mesenchymal stem cells (ADSCs) have therapeutic effects in inflammatory diseases. However, production of extracellular vesicles (EVs) from ADSCs is costly, inefficient, and time consuming. The anti‐inflammatory properties of adipose tissue‐derived EVs and other biogenic nanoparticles have not been explored. In this study, biogenic nanoparticles are obtained directly from lipoaspirate, an easily accessible and abundant source of biological material. Compared to ADSC‐EVs, lipoaspirate nanoparticles (Lipo‐NPs) take less time to process (hours compared to months) and cost less to produce (clinical‐grade cell culture facilities are not required). The physicochemical characteristics and anti‐inflammatory properties of Lipo‐NPs are evaluated and compared to those of patient‐matched ADSC‐EVs. Moreover, guanabenz loading in Lipo‐NPs is evaluated for enhanced anti‐inflammatory effects. Apolipoprotein E and glycerolipids are enriched in Lipo‐NPs compared to ADSC‐EVs. Additionally, the uptake of Lipo‐NPs in hepatocytes and macrophages is higher. Lipo‐NPs and ADSC‐EVs have comparable protective and anti‐inflammatory effects. Specifically, Lipo‐NPs reduce toll‐like receptor 4‐induced secretion of inflammatory cytokines in macrophages. Guanabenz‐loaded Lipo‐NPs further suppress inflammatory pathways, suggesting that this combination therapy can have promising applications for inflammatory diseases.

show abstract

Section: Resultsmentioning

confidence: 99%

Adipose‐Derived Biogenic Nanoparticles for Suppression of Inflammation

Tian

Ticer

Wang

et al. 2020

Small

View full text Add to dashboard Cite

show abstract

“…HDL has been shown to attenuate apoptosis, improve cell survival, preserve mitochondrial function, attenuate oxidative stress2526, as well as to promote glucose uptake by cardiomyocytes27. Furthermore, by inducing the expression and activity of endothelial nitric oxide synthase, HDL increases vascular NO bioavailability5, thereby promoting vasorelaxation of the coronary arteries and, in turn, perfusion of the failing heart.…”

Section: Discussionmentioning

confidence: 99%

Serum Concentration of HDL Particles Predicts Mortality in Acute Heart Failure Patients

Potočnjak

Degoricija

Trbušić

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Clinical studies have shown that assessing circulating concentrations of high-density lipoprotein (HDL) particles by nuclear magnetic resonance (NMR) spectroscopy is superior to HDL-cholesterol in predicting cardiovascular risk. We tested the hypothesis that circulating concentrations of HDL particles predict 3-month mortality of patients with acute heart failure (AHF). Out of 152 included patients, 52% were female, additionally the mean patient age was 75.2 ± 10.3 years, and three-month mortality was 27%. Serum lipoprotein profile at admission was determined by NMR spectroscopy. Univariate logistic regression analyses revealed a significant inverse association of total (odds ratio (OR) 0.38 per 1-SD increase, 95% confidence interval (CI) 0.23–0.60, p < 0.001) and small HDL particle concentrations (OR 0.35 per 1-SD increase, 95% CI 0.19–0.60, p < 0.001) with 3-month mortality, whereas concentrations of large HDL particles (p = 0.353) or HDL-cholesterol (p = 0.107) showed no significant association. After adjustment for age, sex, mean arterial pressure, low-density lipoprotein cholesterol, glomerular filtration rate, urea, and N-terminal pro-brain natriuretic peptide, both the total and small HDL particle concentrations remained significantly associated with 3-month mortality. Based on our results, we conclude that total and small HDL particle concentrations strongly and independently predict 3-month mortality in AHF patients.

show abstract

“…The relation of HDL to heart failure-related deaths in our population would be an interesting area of future study given the evidence that HDL appears to have beneficial effects on ventricular remodeling and myocardial tissue repair. 40 Due to insufficient adjudicated incident CVD events - such as myocardial infarction - we did not have the power to perform a comparative analysis of HDL subclasses in relation to CVD events versus all-cause mortality. Overall, the differential associations of HDL parameters with specific clinical outcomes warrant further investigation.…”

Section: Discussionmentioning

confidence: 99%

High-density lipoprotein subclass measurements improve mortality risk prediction, discrimination and reclassification in a cardiac catheterization cohort

et al. 2016

View full text Add to dashboard Cite

Background and Aims Recent failures of HDL cholesterol (HDL-C)-raising therapies to prevent cardiovascular disease (CVD) events have tempered the interest in the role of HDL-C in clinical risk assessment. Emerging data suggest that the atheroprotective properties of HDL depend on specific HDL particle characteristics not reflected by HDL-C. The purpose of this study was to determine the association of HDL particle concentration (HDL-P) and HDL subclasses with mortality in a high-risk cardiovascular population and to examine the clinical utility of these parameters in mortality risk discrimination and reclassification models. Methods Using nuclear magnetic resonance spectroscopy, we measured HDL-P and HDL subclasses in 3972 individuals enrolled in the CATHGEN coronary catheterization biorepository; tested for association with all-cause mortality in robust clinical models; and examined the utility of HDL subclasses in incremental mortality risk discrimination and reclassification. Results Over an average follow-up of eight years, 29.6% of the individuals died. In a multivariable model adjusted for ten CVD risk factors, HDL-P [HR, 0.71 (0.67-0.76), p= 1.3e-24] had a stronger inverse association with mortality than did HDL-C [HR 0.93 (0.87-0.99), p=0.02]. Larger HDL size conferred greater risk and the sum of medium- and small-size HDL particles (MS-HDL-P) conferred less risk. Furthermore, the strong inverse relation of HDL-P levels with mortality was accounted for entirely by MS-HDL-P; HDL-C was not associated with mortality after adjustment for MS-HDL-P. Addition of MS-HDL-P to the GRACE Risk Score significantly improved risk discrimination and risk reclassification. Conclusion HDL-P and smaller HDL subclasses were independent markers of residual mortality risk and incremental to HDL-C in a high-risk CVD population. These measures should be considered in risk stratification and future development of HDL-targeted therapies in high-risk populations.

show abstract

Therapeutic Potential of HDL in Cardioprotection and Tissue Repair

Cited by 43 publications

References 208 publications

Adipose‐Derived Biogenic Nanoparticles for Suppression of Inflammation

Adipose‐Derived Biogenic Nanoparticles for Suppression of Inflammation

Serum Concentration of HDL Particles Predicts Mortality in Acute Heart Failure Patients

High-density lipoprotein subclass measurements improve mortality risk prediction, discrimination and reclassification in a cardiac catheterization cohort

Contact Info

Product

Resources

About